Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call
Marinus Pharmaceuticals (Nasdaq: MRNS) has rescheduled its Fiscal Q1 2021 financial results conference call from May 13 to May 17, 2021, at 8:30 AM ET. This change does not alter the access details for participants. Marinus is focused on developing therapies for rare seizure disorders, primarily through its drug Ganaxolone, which modulates GABAA receptors. The company recently completed a Phase 3 trial for CDKL5 deficiency disorder and has ongoing trials for tuberous sclerosis complex and refractory status epilepticus.
- Successful completion of the first-ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder.
- Active clinical trials for tuberous sclerosis complex and refractory status epilepticus.
- None.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it has rescheduled its Fiscal First Quarter 2021 financial results conference call, originally scheduled for Thursday May 13, 2021 at 4:30 PM Eastern. The call will now be held on Monday, May 17 at 8:30 AM ET.
Access to the call remains the same as originally planned:
Domestic: (833) 979-2765
International: (343) 761-2590
Webcast Link: https://event.on24.com/wcc/r/3081130/88D98EC340CEF9104A24FACA2A4283B7
Conference ID: 6864408
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, is conducting a Phase 2 trial in tuberous sclerosis complex and has recently disclosed top line results from its Phase 2 proof-of-concept trial in PCDH19-related epilepsy. The company has initiated a Phase 3 trial in refractory status epilepticus. For more information visit www.marinuspharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005741/en/
FAQ
When is Marinus Pharmaceuticals' new conference call date for Q1 2021 results?
What drug is Marinus Pharmaceuticals developing for seizure disorders?
What recent trial has Marinus Pharmaceuticals completed?
What are the ongoing trials for Marinus Pharmaceuticals?
